Edgewise Therapeutics (EWTX) Free Cash Flow (2020 - 2026)

Edgewise Therapeutics has reported Free Cash Flow over the past 7 years, most recently at -$42.6 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$42.6 million for Q1 2026, down 12.33% from a year ago — trailing twelve months through Mar 2026 was -$148.7 million (down 25.8% YoY), and the annual figure for FY2025 was -$144.1 million, down 32.09%.
  • Free Cash Flow reached -$42.6 million in Q1 2026 per EWTX's latest filing, down from -$38.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$11.8 million in Q4 2022 and bottomed at -$42.6 million in Q1 2026.
  • Median Free Cash Flow over the past 5 years was -$27.0 million (2023), compared with a mean of -$26.4 million.
  • The largest annual shift saw Free Cash Flow crashed 129.03% in 2023 before it rose 0.72% in 2024.
  • Over 5 years, Free Cash Flow stood at -$11.8 million in 2022, then plummeted by 129.03% to -$27.0 million in 2023, then increased by 0.72% to -$26.8 million in 2024, then plummeted by 44.8% to -$38.8 million in 2025, then dropped by 9.75% to -$42.6 million in 2026.
  • Business Quant data shows Free Cash Flow for EWTX at -$42.6 million in Q1 2026, -$38.8 million in Q4 2025, and -$34.7 million in Q3 2025.